CBP-1029

CBP-1029 is a bispecific antibody-drug conjugate (ADC) being developed by Coherent Biopharma for the treatment of solid cancers. It utilizes the company's proprietary Bi-XDC (bi-targeting ligand-drug conjugate) technology platform to deliver a topoisomerase inhibitor payload directly to tumor cells. The Bi-XDC platform is designed to enhance tumor specificity and therapeutic index by targeting two distinct antigens simultaneously. While the specific molecular targets for CBP-1029 have not been publicly disclosed, the drug is part of a pipeline of next-generation conjugates aimed at overcoming resistance and reducing systemic toxicity in oncology. It is currently in the early stages of development.